InMed Pharmaceuticals (INM)
NASDAQ:INM
Want to see INM full AI Analyst Report?
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.58 - $7.98
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$2.15M
Enterprise Value-$5.13B
Total Cash (Recent Filing)$5.20B
Total Debt (Recent Filing)$30.77M
Price to Earnings (P/E)―
Beta3.30
Next Earnings
Sep 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1141.81
Shares Outstanding3,314,063
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap-2.38K
Enterprise Value/Revenue-7.72
Enterprise Value/Gross Profit-75.19
Enterprise Value/Ebitda28.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetVery low debt-to-equity (~0.4% TTM) materially reduces refinancing and interest burden risk, giving management structural financial flexibility. Over 2-6 months this conservatism lowers near-term solvency risk and increases optionality to raise capital or execute strategic priorities without heavy leverage constraints.
Robust INM-901 Preclinical Translational Data And Clinical PathConsistent anti-inflammatory effects across in vivo, ex vivo and human organoid systems materially de-risk INM-901's translational case. With a planned U.S. pre-IND meeting (Q3 2026) and targeted Phase 1 in 2027, the program creates durable pipeline value and a clear regulatory path for potential partnerships or licensing.
Manufacturing Scale-up And Regulatory Preparation For PipelineProgress on formulation, manufacturing scale-up and IND-enabling work strengthens execution capacity for clinical studies and later supply. This builds a lasting operational capability that supports clinical timelines, reduces technical supply risk, and improves attractiveness to partners or contract manufacturers.
Bears Say
Deep Negative Operating And Free Cash FlowSustained, large negative operating and free cash flow in the trailing twelve months creates persistent financing need. Over the next 2-6 months this elevates dilution and funding risk, forces distracting capital raises, and constrains discretionary R&D and development spending absent near-term financing.
Wind-down Of BayMedica Removes Revenue-generating UnitExiting BayMedica eliminates the company's primary commercial revenue source, structurally shifting revenues toward milestone-driven, long-dated pipeline outcomes. This increases near-term liquidity reliance on capital markets and magnifies execution risk since operating cash must be replaced by financing or future clinical successes.
Nasdaq Minimum Bid-price Noncompliance And Listing RiskA 30-day failure to meet the $1 bid-price triggers a 180-day cure period and potential reverse split or delisting. This structural listing risk can limit liquidity, complicate capital raises, and force management actions (reverse split, appeals) that can distract from clinical execution and increase governance/market access uncertainty.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.57 and its highest was $7.98 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $2.15M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 18, 2026 which is in 131 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.733 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.733.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 3,314,063 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Ownership Overview
11.67%
Insiders
0.15% Other Institutional Investors
88.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---